Comparative Pharmacology
Head-to-head clinical analysis: SALPIX versus SODIUM FLUORIDE F 18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SALPIX versus SODIUM FLUORIDE F 18.
SALPIX vs SODIUM FLUORIDE F-18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SALPIX (sodium chloride 0.9%, benzyl alcohol 0.9%) is a sterile, nonpyrogenic isotonic solution. It does not have a direct pharmacological mechanism of action; it is used as a vehicle or diluent for other medications and for irrigation. The benzyl alcohol component acts as a bacteriostatic preservative.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
SALPIX (hysterosalpingography contrast medium) is administered intrauterine as a single dose of 10-20 mL, instilled slowly under fluoroscopic guidance. No systemic dosing; procedure is diagnostic.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.0 hours. Short half-life necessitates frequent dosing in clinical use.
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
Primarily renal excretion as unchanged drug: >90% within 24 hours. Minor biliary/fecal elimination (<10%).
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical